Ardelyx Inc ARDX

NAS: ARDX | ISIN: US0396971071   19:27
6,520 USD (+3,33%)
(+3,33%)   19:27

25 oktober 2023 · Thinking about buying stock in VinFast Auto, Ardelyx, Harpoon Therapeutics, Mind Technology, or Ault Alliance? · Persbericht

24 oktober 2023 · Thinking about buying stock in VinFast Auto, Ardelyx, Harpoon Therapeutics, Mind Technology, or Ault Alliance? · Persbericht

20 oktober 2023 · Thinking about buying stock in Ardelyx, Rivian Automotive, Femasys, Lucid Group, or Outlook Therapeutics? · Persbericht

19 oktober 2023 · Thinking about buying stock in Ardelyx, RVL Pharmaceuticals, Wheeler Real Estate Investment Trust, Troika Media Group, or AT&T? · Persbericht

18 oktober 2023 · Thinking about buying stock in Tempest Therapeutics, VinFast Auto, AGNC Investment, Ardelyx, or Viking Therapeutics? · Persbericht

2 februari 2023 · Ardelyx, Inc. Reports Employment Inducement Grants · Persbericht

29 december 2022 · FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor) · Persbericht

23 december 2022 · Ardelyx, Inc. Reports Employment Inducement Grants · Persbericht

17 december 2022 · Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis · Persbericht

22 november 2022 · Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference · Persbericht

17 november 2022 · Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis · Persbericht

16 november 2022 · Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis · Persbericht

4 november 2022 · National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels · Persbericht

3 november 2022 · Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights · Persbericht

3 november 2022 · Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis · Persbericht

2 november 2022 · Ardelyx, Inc. Reports Employment Inducement Grants · Persbericht

31 oktober 2022 · Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan · Persbericht

27 oktober 2022 · Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022 · Persbericht

24 oktober 2022 · Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting · Persbericht

20 oktober 2022 · Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022 · Persbericht

Mijn selecties